- Zoetis reported Q3 2025 revenue of $2.4 billion, up 1% year-over-year, and net income of $721 million, or $1.63 per diluted share.
- Organic operational growth reached 4% for revenue and 9% for adjusted net income.
- Adjusted net income totaled $754 million, or $1.70 per diluted share.
- Full-year 2025 revenue guidance revised to $9.4–$9.475 billion, reflecting 5.5%–6.5% organic operational growth.
- Adjusted diluted EPS guidance maintained at $6.30–$6.40 for fiscal 2025.
Zoetis Inc. (NYSE: ZTS) reported financial results for the third quarter of 2025, delivering $2.4 billion in revenue, a 1% increase compared to the same period last year. On an organic operational basis, revenue rose 4%, while net income climbed 6% to $721 million, or $1.63 per diluted share. Adjusted net income increased 5% to $754 million, or $1.70 per diluted share, with 9% growth on an organic operational basis.
“We reported 4% organic operational revenue growth and 9% growth in adjusted net income thanks to the consistent execution of our colleagues across the globe,” said Kristin Peck, Chief Executive Officer of Zoetis. “While growth moderated in line with expectations, we achieved significant regulatory milestones across products and species, reinforcing our pipeline strength and commitment to advancing animal health.”
In the U.S. segment, revenue totaled $1.3 billion, down 2% on a reported basis but up 3% organically, driven by strong livestock and parasiticide performance offsetting slower sales of monoclonal antibody therapies Librela® and Solensia®. International revenue reached $1.1 billion, up 3% reported and 6% organically, supported by growth across the dermatology, parasiticide, and vaccine portfolios.
Zoetis continues to drive innovation across its pipeline with regulatory milestones including Canadian approval of Lenivia® for osteoarthritis pain in dogs and EU approval of Portela® for osteoarthritis pain in cats. The company also expanded dermatology and parasiticide labels globally, launched its AI-powered Vetscan® Opticell™ hematology analyzer in the EU, and received FDA conditional approval for Dectomax®-CA1 to combat New World screwworm in cattle.
For fiscal year 2025, Zoetis updated its full-year guidance to reflect broader macro trends and disciplined cost control, with expected revenue of $9.4–$9.475 billion and adjusted net income of $2.8–$2.84 billion. Adjusted diluted EPS is projected at $6.30–$6.40, with organic operational growth in adjusted net income between 5.5% and 7.0%.
The company will host a webcast and conference call to review third quarter results and financial guidance, with a replay available on its investor website.
Information sourced from the company’s press release.
